Navigation Links
Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimer's Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
Date:8/26/2013

OSAKA, Japan and DURHAM, N.C., Aug. 26, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), today announced the initiation of TOMMORROW, a global Phase 3 clinical trial investigating a genetic-based biomarker risk assignment algorithm (risk assignment algorithm) to predict risk of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) within a five year period and to evaluate the efficacy of the investigational low dose pioglitazone (designated AD-4833 for this use) in delaying the onset of MCI due to AD in cognitively normal individuals at high risk as determined by the risk assignment algorithm.

The risk assignment algorithm is comprised of apolipoprotein E (APOE) and TOMM40 genotypes and age. Age and APOE genotype have previously been shown to indicate elevated risk of AD. The addition of TOMM40 is hypothesized to further refine the risk determination.

"To date, there have been a number of avenues investigated with the goal of altering the course of Alzheimer's disease but results have been unsuccessful," said Allen Roses, M.D., Chief Executive Officer, Zinfandel. "This is why the TOMMORROW trial is important. The potential to identify an individual's risk for developing MCI due to AD warrants further investigation."

AD is a devastating disease and diagnoses are increasing as the world's population ages. Currently 35.6 million people worldwide are living with some form of dementia. Studies show that individuals with MCI are at an increased risk of developing AD or another dementia with conversion rates of approximately 15 percent per year.

"AD-4833 is a member of a class of drugs known as PPAR (peroxisome proliferator-activated receptor)-gamma agonists which available data show may have a beneficial role in delaying symptoms of MCI due to AD," noted '/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Launches New Subsidiary in Peru
2. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
3. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
4. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
5. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
6. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
7. Takeda to Acquire Inviragen, Inc.
8. Takeda Responds to Verdict in Diabetes Drug Case
9. Takeda Launches New Subsidiary in Ecuador
10. Takeda lanza nueva subsidiaria en Ecuador
11. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  Amgen (NASDAQ: AMGN ) ... year 2014 financial results on Tuesday, Jan. 27, 2015, after the ... by a conference call with the investment community at 2 p.m. ... A. Bradway , chairman and chief executive officer, and other members ...
(Date:1/22/2015)... Calif. , Jan. 22, 2015 Increasing sophistication ... continued consolidation of localization purchasing in 2015, says ... According to a recent study by market research firm ... a single-source solution for their translation and localization needs. ...
(Date:1/22/2015)... ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the addition of ... by End User - Global Forecast to 2019" report ... market is valued at $1,228.58 million in 2014 and is ... $2,230.72 million by 2019. Allergy diagnostics is used to determine ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... BELGRADE, Mont., Nov. 15, 2010 Bacterin International Holdings, ... BIHI ), a developer of anti-infective coatings for ... financial results for its third quarter ended September 30, ... the reverse merger transaction reported in the Company,s Form ...
... Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical ... 2010 Scrip Award for "Clinical Research Team of ... at the sixth annual Scrip Awards ceremony, hosted ... information service for the global pharmaceutical industry, on November 4, ...
Cached Medicine Technology:Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 2Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 3Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 4Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 5Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 6Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 7Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 8Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 9PAREXEL Wins Clinical Research Team of the Year Scrip Award 2PAREXEL Wins Clinical Research Team of the Year Scrip Award 3PAREXEL Wins Clinical Research Team of the Year Scrip Award 4PAREXEL Wins Clinical Research Team of the Year Scrip Award 5
(Date:1/22/2015)... 22, 2015 Autocarinsurancebest.com has released a new ... commercial auto insurance policy . , Auto insurance quotes ... It is no longer necessary to call an agent or ... available online on a single website: http://autocarinsurancebest.com/ . , ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... Four years since the release of their debut ... the marriage of Avasa & Matthew Love – the duo are ... for release through White Swan Records on February 24, 2015. , ... sacred path available to all of us to walk out of ...
(Date:1/22/2015)... January 22, 2015 JJsHouse.com is a famous ... Today, the business announces its latest collection of wedding ... “The most important issue is the wedding dress on your ... in a woman’s life. Every bride wants to find the ...
(Date:1/22/2015)... USA (PRWEB) January 22, 2015 State ... statewide data management system with support from GEOSYSTEMS, a ... The new solution will leverage Hexagon Geospatial’s ERDAS ... vector data as well as point clouds and documents. ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... Oct. 11 At "Managing Quality to,Drive Growth," ... LLC,s,Global Benchmarking Council (GBC), executives from 20 leading ... for quality and,growth; product innovation excellence; process simplification ... successes in integrating quality into,sales, marketing and new ...
... ALOKA Co., Ltd., a pioneer in the,development ... Masanobu Tada as President, and Carlos Faustmann as ... the company,s,wholly-owned European headquarters in Zug, Switzerland, with ... Global Marketing of the company as,general manager since ...
... YORK, Oct. 10 Molina Healthcare Inc. (NYSE: MOH ... in the S&P,SmallCap 600 after the close of trading on ... constituent LKQ Corp. (Nasdaq: LKQX ) in,a deal that ... final,approvals. Standard & Poor,s will monitor this transaction, and ...
... PORTLAND, Ore., Oct. 10 Mark Ganz, President and ... a prominent group of,thought leaders and health policy experts ... major initiative to reframe and broaden the,national dialogue on ... and beyond. The Aspen Health Stewardship Project will ...
... performed equally in high-tech tests , , WEDNESDAY, Oct. 10 ... runners should follow Prince Charming,s lead and consider a ... , Using high-tech methods, a team of Scottish scientists ... between $80 pairs of running shoes and pairs made ...
... to Protect Health Benefit, MARYSVILLE, Calif., Oct. 10 ... to announce the filing of a,formal grievance over the ... caregivers earlier this year. Because of the county,s ... residents who are elderly or have disabilities must play,a ...
Cached Medicine News:Health News:Mastering Challenges & Measuring Successes for Quality Initiatives in Sales, Marketing and Product Development 2Health News:ALOKA Appoints New Management in Europe 2Health News:Standard & Poor's Announces Change to U.S. Index 2Health News:Regence CEO to Chair National Effort Promoting Broader Health Care Stewardship 2Health News:Regence CEO to Chair National Effort Promoting Broader Health Care Stewardship 3Health News:Pricey Running Shoes Not Worth It: Study 2Health News:Pricey Running Shoes Not Worth It: Study 3Health News:Pricey Running Shoes Not Worth It: Study 4Health News:Caregivers Demand County Honor Their Contract 2
Mounted on a fully adjustable molded,headband with crown strap and comfort,cushions, the sturdy Trueview Classic is,lightweight, comfortable and durable....
Mounted on a fully adjustable molded,headband with crown strap and comfort,cushions, the sturdy Halogen III Classic is,lightweight, comfortable and durable....
Mounted on a sturdy, molded headband,the Classic has a fully adjustable,crown strap and cushioning that adds,to your comfort....
... InterGro DBM putty is a ... most trusted names in human tissue ... in bone grafting technology. InterGro ... lipid carrier (lecithin) to deliver a ...
Medicine Products: